J&J Vaccine Guards Against Delta Variant, Company Says

FRIDAY, July 2, 2021 (HealthDay News) — Johnson & Johnson announced Thursday that its COVID-19 vaccine is effective against the highly contagious Delta variant that brought India to its knees this past spring.

The finding will no doubt reassure the 11 million Americans who have gotten the J&J shot, as the company also noted the protection lasted eight months after inoculation. Although there was a slight drop in potency against the Delta variant, data from two studies show the J&J vaccine was more effective against the Delta variant than the Beta variant that first surfaced in Africa. Even better, antibodies stimulated by the J&J vaccine grew in strength over time, the company added.

Both studies, which have been submitted for online publication on the preprint server bioRxiv, were small, but the company said it released the results early because of high public interest.

“Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help protect the health of people globally,” Paul Stoffels, M.D., vice chairman of the executive committee and chief scientific officer at Johnson & Johnson, said in a company news release. “We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant. This adds to the robust body of clinical data supporting our single-shot vaccine’s ability to protect against multiple variants of concern.”

More Information